USFDA Completes Inspection At Granules India’s Hyderabad Facility

US FDA has completed inspection of the facility in Gagillapur located in Hyderabad, Telangana, India on 14th February 2020 with two observations. Granules India Limited will respond to these observations within the stipulated time.

“We successfully completed an FDA audit with two observations, which are being addressed and will respond to the FDA within the stipulated time. These observations will not affect the business continuity.” said Krishna Prasad, Chairman an. Managing director, Granules India Limited, commenting on the US FDA Audit.

Shares of GRANULES INDIA LTD. was last trading in BSE at Rs.175.65 as compared to the previous close of Rs. 169.85. The total number of shares traded during the day was 301432 in over 6301 trades.

The stock hit an intraday high of Rs. 179.55 and intraday low of 168.15. The net turnover during the day was Rs. 52703394.-Equity Bulls